Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer

Paula I. Gonzalez-ericsson, Julia D. Wulfkhule, Rosa I. Gallagher, Xiaopeng Sun, Margaret L. Axelrod, Quanhu Sheng, Na Luo, Henry Gomez, Violeta Sanchez, Melinda Sanders, Lajos Pusztai, Emanuel Petricoin, Kim R.m. Blenman, David A Potter, Justin M. Balko

Research output: Contribution to journalArticlepeer-review

36 Scopus citations
Original languageEnglish (US)
Pages (from-to)5299-5306
JournalClinical Cancer Research
Issue number19
StatePublished - Oct 1 2021

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

Cite this